Annals of Indian Academy of Neurology
  Users Online: 8737 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size

Table of Contents
Year : 2022  |  Volume : 25  |  Issue : 3  |  Page : 502

Dose of isoniazid in renal disease for treatment of tuberculosis

Department of Neurology, St. John's Medical College Hospital, Bangalore, Karnataka, India

Date of Submission13-Aug-2021
Date of Acceptance17-Aug-2021
Date of Web Publication12-Jan-2022

Correspondence Address:
G Sarma
Department of Neurology, St. John's Medical College Hospital, Johnnagar, Bangalore - 560 076, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aian.aian_729_21

Rights and Permissions


How to cite this article:
Sarma G. Dose of isoniazid in renal disease for treatment of tuberculosis. Ann Indian Acad Neurol 2022;25:502

How to cite this URL:
Sarma G. Dose of isoniazid in renal disease for treatment of tuberculosis. Ann Indian Acad Neurol [serial online] 2022 [cited 2022 Aug 9];25:502. Available from:


I read with interest the paper on Isoniazid induced cerebellitis by Shah VS and Sardana V in the recent AIAN journal.[1] The authors described a patient with chronic renal disease, on 375 mg of isoniazid without pyridoxine supplements, who developed cerebellar toxicity. His MRI showed classical dentate signal changes and he made clinical and radiological recovery following withdrawal of isoniazid and addition of pyridoxine. Certainly, the paper is an important reminder for clinicians to be cautious of this complication in renal disease. However, two statements in the discussion section could confuse the clinicians on the appropriate dose of isoniazid in renal disease. The authors initially, and rightly, state that no dose modification of isoniazid is needed in renal disease. But, in the concluding remarks, they infer from this particular case that a dose modification of 'anti tubercular drugs' is indeed needed.

A literature search revealed that the available guidelines advise no dose modification of isoniazid in patients with renal disease, even if they are on hemodialysis.[2] Similarly, no dose modification is needed for rifampicin, pyrazinamide, moxifloxacin and linezolid.[2],[3] Ethambutol can be given in standard doses in stage 1 to 3 Chronic Kidney Disease (CKD) and in patients on hemodialysis, but in stage 4 and 5, 15–25 mg/kg 3×/week (maximum 2.5 g) is recommended. Specific dosing guidelines for other drugs are also available.[3] All drugs need to be given 4–6 hours before the scheduled hemodialysis or after the completion of hemodilaysis. Adherence to the standard guidelines minimizes the risk of drug toxicities as well as under treatment of this serious infection.

To conclude, clinicians can safely use the standard dose of isoniazid in renal disease, which is 5 mg/kg/day, with a maximum of 300 mg/day.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Shah VS, Sardana V. A case of isoniazid induced cerebellitis in a patient with chronic renal failure. Ann Indian Acad Neurol 2021;24:95-7.  Back to cited text no. 1
  [Full text]  
Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, Khoo S, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557-70.  Back to cited text no. 2
Guideline – Treatment of tuberculosis in renal disease. Version 3. 0. Available from:  Back to cited text no. 3


Print this article  Email this article


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (1,280 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal